Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

794P - Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)

Date

21 Oct 2023

Session

Poster session 11

Topics

Clinical Research;  Cancer Biology;  Genetic and Genomic Testing;  Therapy

Tumour Site

Ovarian Cancer

Presenters

Jerold Loh

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

J. Loh1, N.Y.L. Ngoi2, F. Blanc-Durand3, S.Y.R. Ang4, E. Elias4, A. Lai5, D. Lim6, Y.W. Lim4, S.E. Lim7, J. Low8, J. Ng9, V. Sundararajan10, Y.L. Thian11, P. Tong12, S. Wijaya13, D.S. Tan14

Author affiliations

  • 1 Medical Oncology, National University Cancer Institute (NCIS), 119074 - Singapore/SG
  • 2 Department Of Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, 570221 - Singapore/SG
  • 3 Medical Oncology Dept., Institut Gustave Roussy, 570221 - Singapore/SG
  • 4 Medical Oncology, NCIS - National University Cancer Institute Singapore, 119074 - Singapore/SG
  • 5 Geriatrics, NUH - National University Hospital (S) Pte. Ltd., 119074 - Singapore/SG
  • 6 Pathology, Cancer Science Institute (CSI) - National University of Singapore (NUS), 117599 - Singapore/SG
  • 7 Hematology-oncology, NCIS - National University Cancer Institute Singapore, 119074 - Singapore/SG
  • 8 Obstetrics And Gynaecology, NUS-National University of Singapore-National University Health System (NUHS), 119228 - Singapore/SG
  • 9 Obstetrics And Gynaecology, NUHS - National University Health System, 119228 - Singapore/SG
  • 10 Clinical Research, Cancer Science Institute (CSI) - National University of Singapore (NUS), 117599 - Singapore/SG
  • 11 Radiology, NUH - National University Hospital (S) Pte. Ltd., 119074 - Singapore/SG
  • 12 Obstetrics And Gynaecology, national university hospital, hospital, 117599 - Singapore/SG
  • 13 Medical Oncology, NCIS - National University Cancer Institute Singapore, 570221 - Singapore/SG
  • 14 Medical Oncology Department, NUHS - National University Health System, 570221 - Singapore/SG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 794P

Background

OCCC, compared to other histologies, are less responsive to platinum based chemotherapy and suffer a worse prognosis. ARID1A mutations (mt) are the most common mt in OCCC. ARID1A loss has been described to increase replication stress in various tumor models. Anti-metabolites like gem are effective in ARID1A-mt in-vitro.

Methods

We performed a retrospective analysis of the molecular features and treatment outcomes of advanced or relapsed OCCC pts treated at our institution between January 2000 to May 2022. Treatment response was assessed per RECIST1.1. Next-generation sequencing (NGS) was performed where sufficient archival tissue was available (n=60). We hypothesize that gem is more effective than non-gem therapies, especially in ARID1A-mt.

Results

Of 90 advanced or relapsed OCCC patients (pts), median age was 53 years, with median 1 prior line of treatment received. 67 (74.4%) received 2 or more lines, of whom 35 (52.2%) included gem based therapy, mostly in 2nd line (19/35). 12 pts received platinum-gem with bevacizumab (bev), 18 pts received platinum-gem, 5 received gem monotherapy. 30/60 (50%) were ARID1A-mt. Across all treatment lines, the disease control rate (DCR) to gem was 61.1%. In 2nd line, DCR was significantly better for gem over non gem (Odds Ratio (OR) OR 6.5, p=0.004), seemingly more for ARID1A-mt (OR of mt VS wild-type (wt) 28 VS 4.2). Early use of gem (2nd against later lines) and incorporation of bev significantly improved DCR on multivariate analysis (Early use OR 4.1, p: 0.04; Bev OR 7.2, p: 0.02). There was a trend to improved median progression-free survival (mPFS) of 2L gem against non-gem based therapy (7.2 versus 3.2 months(m); Hazard Ratio (HR): 3.48, p = 0.06). This was significant in ARID1A mts (gem VS non-gem: 295 VS 70 days; HR: 4.3, p=0.04) but not in ARID1A-wt (p=0.14). Overall survival was not statistically significant in this study.

Conclusions

This is the largest study of OCCC pts receiving gem based therapy. We show that gemcitabine improved DCR for all OCCC patients, and mPFS in ARID1A-mt especially when used earlier. To maximise gem efficacy, earlier treatment combined with bevacizumab should be considered in OCCC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

N.Y.L. Ngoi: Financial Interests, Institutional, Invited Speaker: MSD, AstraZeneca, ASGO, JSGO; Financial Interests, Institutional, Advisory Board: Merck/Pfizer, AstraZeneca. F. Blanc-Durand: Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Member of Board of Directors: Cureety; Financial Interests, Institutional, Research Grant: AZ; Other, Travel: GSK. D.S. Tan: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Merck Serono, Roche, Eisai, GSK, Takeda; Financial Interests, Personal, Advisory Board: AstraZeneca, Bayer, MSD, Eisai, Roche, Genmab, GSK, Boehringer Ingelheim; Financial Interests, Personal, Stocks/Shares: Asian Microbiome Library (AMiLi); Financial Interests, Institutional, Research Grant: Roche, Bayer, Karyopharm Therapeutics, AstraZeneca; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Bergen Bio; Financial Interests, Institutional, Local PI: Zeria Pharmaceutical Co., Ltd., Bayer, Byondis B.V.; Non-Financial Interests, Leadership Role, Ex society president: Gynecologic Cancer Group Singapore; Non-Financial Interests, Member of Board of Directors: Gynaecologic Cancer Intergroup (GCIG); Non-Financial Interests, Leadership Role, Ex- Chair: Asia-Pacific Gynecologic Oncology Trials Group (APGOT); Non-Financial Interests, Institutional, Product Samples, Research Study: MSD, Eisai, AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.